Role of bronchoalveolar lavage in immunocompromised patients with pneumonia treated with a broad spectrum antibiotic and antifungal regimen

I A Hohenadel, M Kiworr, R Genitsariotis, D Zeidler, J Lorenz

Abstract

Background—In a retrospective study the value of bronchoalveolar lavage (BAL) in the diagnosis of pneumonia was investigated in 95 immunocompromised patients suffering from haematological disorders and receiving a regimen of broad spectrum antibiotics and antifungal agents (BSAR).

Methods—With the exception of four afebrile patients, all had fever, raised C reactive protein (CRP) levels, and new infiltrates visible on chest radiography. All patients underwent BAL to identify the organism causing the pneumonia and surveillance cultures were performed regularly for pathogens at different sites. Following classification of the isolates, patients with positive cultures were subdivided into two groups, pathogenic or contaminated. We investigated whether relevant pathogens were cultured only from the BAL fluid and whether they were susceptible to BSAR.

Results—Although 77 of the 95 patients were thrombocytopenic, bleeding during BAL occurred in only 15% of all patients. Ten days after the procedure the fever improved in 88% of patients, radiographic findings improved in 71%, and CRP levels improved in 75% of patients; 22% of patients died within 28 days. Pathologically relevant isolates were found in 65% of all patients. Respiratory pathogens were detected only in the BAL fluid of 29 of the 95 patients (35% Gram positive species, 40% Gram negative species, 11% Mycobacterium, 11% fungi, and 3% cytomegalovirus). In 16 of these 29 patients (55%) the pathogens cultured only from the BAL fluid were resistant to treatment. Pathogens detected only in the BAL fluid were not susceptible to a standard broad spectrum antibiotic and antifungal regimen including teicoplanin, ceftriaxon, tobramycin, and amphotericin B in 12 of the 29 patients (41%).

Conclusions—Our data suggest that 12 patients were treated with broad spectrum antimicrobial agents which were not directed at the appropriate organism on in vitro sensitivity tests without BAL. BAL is a relatively safe procedure in the diagnosis of pneumonia, supplying important information in immunocompromised patients as well as in immunocompromised patients receiving BSAR.

Keywords: bronchoalveolar lavage; pneumonia; immunosuppression

Pneumonia is a major cause of death in immunocompromised patients with haematological disorders; the mortality associated with untreated Legionella pneumophila infection in immunocompromised patients has been reported to be 80%. Identification of the causative pathogen and initiation of effective treatment is therefore essential. We have investigated the diagnostic value of bronchoalveolar lavage (BAL) in 95 immunocompromised patients with haematological disorders and clinical signs of acute pneumonia, comparing BAL with non-invasive procedures such as surveillance cultures at different sites. We determined whether the BAL findings are associated with the therapeutic outcome for immunocompromised patients routinely receiving a broad spectrum antibiotic and antifungal regimen (BSAR). All BAL related complications were documented, including those observed for patients with thrombocytopenia. This study assesses the effect of the severity of immunodeficiency on a spectrum of pathogens as well as on the clinical course of pneumonia.

Methods

The retrospective study took place in the Department of Pulmonary Medicine in the University Hospital in Mainz, Germany over a period of 4 years and 2 months. All patients with haematological disorders and neutropenia were enrolled in the study if they presented with signs of acute pneumonia. The median (SD) age of the 95 immunocompromised patients (68 men, 27 women) was 49.4 (14.5) years. Underlying diseases included acute myeloid leukaemia (45), acute lymphoid leukaemia (10), chronic myeloid leukaemia (10), non-Hodgkin’s lymphoma (10), myelodysplastic syndrome (7), Hodgkin’s disease (5), chronic lymphatic leukaemia (3), aplastic anaemia or agranulocytosis (5). Patients were divided into two groups according to the neutrophil granulocyte count: group A included 71 patients with a neutrophil granulocyte count of less than 1000 μl and group B included 24 patients with a neutrophil granulocyte count of 1000–3500 μl. With the exception of four afebrile patients, all patients presented with respiratory symptoms (such as dyspnoea and cough), fever, raised C reactive protein (CRP) levels, and new infiltrates as shown by chest
radiography. BSAR was administered to all those except the patients with renal dysfunction for whom the antibiotic and antifungal prescription was changed.

All patients underwent BAL in our department. After inspection of the transbronchial tree to the subsegmental level, the bronchoscope was wedged into a subsegment bronchus in the area with the most marked radiological abnormality or, in the presence of diffuse infiltration, into the lingula or middle lobe.\(^2\) BAL was performed according to a standard technique\(^1\) using 5–7 20 ml aliquots of normal saline. Suctioning after each bolus yielded a total of 40–100 ml of fluid. Aliquots of lavage fluid were submitted for microscopic examination (Gram, acidin and acid-fast stains) and cultured for aerobic and anaerobic bacteria, fungi, mycobacteria, and viruses quantitatively. Standard culture methods were used. Direct immunofluorescence was employed for the detection of *Legionella pneumophila* as well as cultures and polymerase chain reaction in the last year of the study. For mycobacteria, Ziehl Nielsen acid-fast stains and cultures were performed. Detection of cytomegalovirus was performed by immunofluorescence techniques and human cell cultures. For all pathogenic strains isolated antibiograms were primarily determined. Transbronchial biopsy specimens could only be taken from 11 patients; all the remaining patients had thrombocytopenia and/or coagulopathy. The biopsy specimens were taken from the area of interest or from the lower lobes in the presence of a diffuse infiltration. Only two patients underwent open lung biopsies using an invasive procedure. Radiographs were routinely taken during the 24 hours after the transbronchial biopsy specimens to rule out pneumothorax. Fever, laboratory parameters, radiographs, medication including preceding chemotherapy, and duration of neutropenia were recorded from admission to hospital to discharge. Cultures from BAL fluid, sputum, blood, urine, pharyngeal smears, and smears from other sites were performed regularly for all patients. Patients with positive cultures were subdivided following classification of the isolates into pathogenic or contaminated groups during the 14 days before and after BAL. While colonies of *Legionella* were considered to be pathogenic, coagulase negative *Staphylococcus* or *Candida* were considered to be pathogenic only when cultured several times from different sources in the presence of a consistent clinical course.

To determine the diagnostic value of BAL we investigated whether the respiratory pathogens were sensitive to the treatment as well as to a BSAR consisting of teicoplanin, ceftriaxon, tobramycin, and amphotericin B. This standard BSAR regimen was selected on the basis of our clinical experience and according to published recommendations.\(^1\)

**Results**

**Patient Characteristics**

Seventy one immunocompromised patients were allocated to group A (neutrophil granulocyte count less than 1000/µl) and 24 to group B (neutrophil granulocyte count 1000–3500/µl) according to the severity of the underlying condition. The mean value of the lowest granulocyte count was 590/µl (range 0–3400/µl). Seventy six patients had undergone chemotherapy during the six months preceding BAL (mean 23 days). Nine patients had received a bone marrow transplant. Admission to hospital was on average 18.7 days before BAL (range 0–70 days); 71 patients were admitted for a minimum of five days before the procedure. A total of 71 patients were therefore at risk of “hospital acquired pneumonia” with more virulent pathogens. Onset of fever was noted on average 9.4 days and pulmonary infiltrates were detected 7.7 days preceding BAL. There were no significant differences between groups A and B with respect to age, sex, mean duration of BAL, preceding chemotherapy, or the ratio of patients with chemotherapy and clinical parameters.

Intravenous antibiotics and/or antifungal agents were administered to 82 of the 95 patients (86%) were days before BAL. In 80 of the 95 patients (84%) the antibiotic and/or antifungal regimen was changed during the 10 days after the procedure as a result of BAL findings and/or clinical observations. In 73 of the 95 patients antifungal agents were given intravenously. Most patients received the described standard BSAR regimen. There was no significant difference in the percentage of patients treated with BSAR and the duration of antibiotic therapy between groups A and B. Group A included more patients with underlying acute myeloid leukaemia (p=0.004), while the number of patients with non-Hodgkin’s lymphoma (p=0.015) and Hodgkin’s disease (p=0.014) was greater in group B. Surprisingly, there was no difference in the time from the onset of neutropenia to BAL between the two groups.

**Complications of BAL**

No episodes of collapse, allergic reaction to anaesthesia, or pneumothorax occurred during or after bronchoscopy. Seventy seven of the 95 patients (81%) were thrombocytopenic (median platelet count 38 000/µl). The ratio of patients with thrombocytopenia was significantly higher in group A (p=0.002). The platelet count was below 50 000/µl in 58 patients and below 20 000/µl in 16. No patient had major bleeding complications. Minor limited bleeding was observed in 15% of the patients. Twenty ml norepinephrine (noradrenaline) were administered locally to only one patient with a normal platelet count to stop non-haemodynamic bleeding after transbronchial biopsies. One of the 11 patients who underwent a transbronchial biopsy developed minimal bleeding after the procedure. Additional anaesthetics or sedatives were administered to seven patients with severe coughing. Bronchoscopic examination could not be carried out in

STATISTICAL ANALYSIS

The Wilcoxon test for two samples, the χ² test, and Fisher’s exact test (two sided) were used. Values are expressed as mean (SD). A value of p<0.05 was considered significant.\(^5\)
Role of BAL in immunocompromised patients with pneumonia

The results revealed signs of inflammation in 65 of the 95 patients and malignancy was confirmed in three patients (underlying disease non-Hodgkin’s lymphoma in all three), peribronchial fibrosis was noted in one patient, and signs of a graft-versus-host reaction were seen in another patient. One transbronchial biopsy specimen confirmed the BAL finding of Mycobacterium tuberculosis. In three patients in whom no pathogens were found in the BAL fluid, blood, sputum, or other sites, signs of malignancy were observed in the transbronchial biopsy specimens of two and on cytological examination of the BAL fluid in one; malignancy was therefore the most likely cause of the pulmonary infiltrates and fever in these three patients. Bronchoscopy therefore provided important information in the diagnosis of pulmonary infiltrates in 65 of the 95 patients (68.4%).

COMPARISON OF BAL FINDINGS WITH NECROPSIES AND OPEN LUNG BIOPSY SPECIMENS

Necropsy examination confirmed the BAL findings in two patients with a diagnosis of Candida pneumonia, in one patient with squamous cell carcinoma and concomitant bronchopneumonia, and in one patient with severe interstitial cytomegalovirus pneumonia. Open lung biopsy demonstrated aspergillosis with a cavitation filled with hyphae of Aspergillus fumigatus (aspergilloma) and accompanying bronchopneumonia in two patients in whom BAL had detected no evidence of Aspergillus.

Table 1 Characteristics of patients who died during the 28 days following bronchoalveolar lavage (BAL)

<table>
<thead>
<tr>
<th>Patient no</th>
<th>Group</th>
<th>Isolates from BAL fluid</th>
<th>Isolates from other sources</th>
<th>Death (days after BAL)</th>
<th>Additional comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>B</td>
<td>Enterococcus faecalis</td>
<td>Enterococcus (ph)</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>A</td>
<td>Coagulase negative</td>
<td>Coagulase negative Staphylococcus (ph, b)</td>
<td>15</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>A</td>
<td>Multiresistant Staphylococcus; Enterococcus faecalis</td>
<td>Multiresistant Staphylococcus (b); Enterococcus faecalis</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>A</td>
<td>Legionella pneumophila</td>
<td>Negative</td>
<td>16</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>B</td>
<td>Acinetobacter; B. hermanni</td>
<td>Candida (sp, ph)</td>
<td>18</td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>B</td>
<td>Candida</td>
<td>Candida (ph, sp)</td>
<td>21</td>
<td>Patient refused antifungal therapy after 3 days of treatment</td>
</tr>
<tr>
<td>27</td>
<td>A</td>
<td>Negative</td>
<td>Negative</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>28</td>
<td>A</td>
<td>Legionella pneumophila</td>
<td>Acinetobacter (sp); Staphylococcus aureus (sp, ph)</td>
<td>24</td>
<td></td>
</tr>
<tr>
<td>33</td>
<td>B</td>
<td>M tuberculosis</td>
<td>Negative</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>34</td>
<td>A</td>
<td>Negative</td>
<td>Aspergillus (sp); Candida (sp, ph, f)</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>39</td>
<td>A</td>
<td>Streptococcus mutisphaericus; Staphylococcus</td>
<td>Staphylococcus (ph)</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>44</td>
<td>B</td>
<td>Aspergillus fumigatus; Candida</td>
<td>Aspergillus fumigatus (sp); Candida (sp)</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>47</td>
<td>A</td>
<td>Aspergillus fumigatus; Candida; Streptococcus; Lactobacillus</td>
<td>Candida (sp, f)</td>
<td>15</td>
<td>Necropsy: fungal pneumonia</td>
</tr>
<tr>
<td>48</td>
<td>A</td>
<td>Multiresistant Staphylococcus</td>
<td>Negative</td>
<td>26</td>
<td></td>
</tr>
<tr>
<td>60</td>
<td>B</td>
<td>Negative</td>
<td>Negative</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>64</td>
<td>A</td>
<td>Enterococcus faecalis</td>
<td>Negative</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>70</td>
<td>B</td>
<td>Candida</td>
<td>Candida (ph); Klebsiella pneumonia (ph)</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>71</td>
<td>A</td>
<td>Negative</td>
<td>Negative</td>
<td>20</td>
<td>ARDS, pneumothorax related to mechanical ventilation</td>
</tr>
<tr>
<td>78</td>
<td>B</td>
<td>Candida</td>
<td>Candida (ph, f); Staph aureus (ph)</td>
<td>19</td>
<td></td>
</tr>
<tr>
<td>90</td>
<td>B</td>
<td>Cytomegalovirus; Candida; Staphylococcus; Lactobacillus</td>
<td>Candida (u, f, sp, ph); Staphylococcus (sp, ph)</td>
<td>7</td>
<td>Necropsy: cytomegalovirus pneumonia</td>
</tr>
</tbody>
</table>

ph = pharyngeal smears; sp = sputum; b = blood; f = faeces; u = urine.
view of the fact that open lung biopsy is an invasive procedure, it is rarely performed in patients with leukopenia because of concomitant thrombocytopenia and the risk of bleeding. A statistical analysis could therefore not be performed. A strong correlation was established between the BAL fluid and necroscopic findings, although pathogens such as *Aspergillus* are not detected by BAL if they are localised in cavitations.

**MICROBIOLOGICAL FINDINGS**

Surveillance cultures at different sites were regularly performed for 95 immunocompromised patients with signs of acute pneumonia. Positive cultures were found in BAL fluid (91%), blood (13%), sputum (93%), urine (12%), pharyngeal smears (88%), and other sources including smears obtained from central vein catheters, endotracheal tubes, and pleura fluid (47%). Pathogenically relevant isolates from the respective sources were detected in BAL fluid (65%), blood (11%), sputum (70%), urine (6%), pharyngeal smears (59%), and smears from other sources (30%). The results of cultured pathogenic colonies from BAL fluid are presented in table 2.

In 62 of the 95 patients (65%) a pathogen likely to be responsible for pneumonia was cultured from the BAL fluid. In 36 of these 62 patients (58%) microbiological findings showed the pathogens from the BAL fluid to be resistant to the treatment given. The ratio of patients receiving inadequate treatment was significantly higher (p=0.006) in group B than in group A. If all 62 patients had undergone treatment with a BSAR consisting of teicoplanin, ceftriaxion, tobramycin, and amphotericin B, the treatment would have been ineffective in 20 of the 62 patients (32%) in whom pathogens were detected in the BAL fluid. The following pathogens were resistant to BSAR: *Mycobacterium tuberculosis* or *M xenopi*, *Capnocytophaga*, multiresistant *Staphylococcus*, *Staphylococcus aureus*, *Stenotrophomonas*, *Acinetobacter*, *Legionella*, *Chlamydia*, and cytomegalovirus.

In 29 of the 95 patients (31%) the organism responsible for pneumonia was detected only in the BAL fluid (35% Gram positive species, 40% Gram negative species, 11% *Mycobacterium*, 11% fungi, 3% cytomegalovirus). Microbiological findings showed that pathogens cultured only in the BAL fluid were resistant to the treatment given in 16 of the 29 patients (55%). Thus, without BAL, 44% of the patients in group A and all of the patients in group B would have been treated with antimicrobial agents which were not directed at the appropriate organism (p=0.02). If all 29 patients had received a BSAR consisting of teicoplanin, ceftriaxion, tobramycin, and amphotericin B, the regimen would have been ineffective in 12 of the 29 patients (41%). With BSAR, 13% of all patients would have received insufficient treatment.

There were no differences between the two groups with regard to positive cultures or pathogens with the exception of *Candida* detected in BAL fluid. The significantly lower incidence of *Candida* in group A than in group B (p=0.005) may be because antifungal therapy was administered to more patients in this group. Antifungal agents were given to 61% of patients in group A and to only 25% of patients in group B. No significant correlation was observed between the individual pathogen and the outcome or the severity of immunosuppression or duration of neutropenia with the exception of mycobacteria which were associated with a longer duration of neutropenia (p=0.03). We could not establish a relationship between the location of pathogens and the susceptibility to antibiotics or antifungal agents and the outcome of treatment.

**Discussion**

We have compared the diagnostic value of BAL as an invasive procedure in 95 immunocompromised patients with haematological disorders and signs of pneumonia with non-invasive procedures such as surveillance cultures at different sites. BAL and sputum had the highest diagnostic yields. However, in assessing this result consideration has to be given to the fact that, in our study, only one culture was taken from the BAL fluid compared with multiple sputum samples (up to 12) and samples from different sources. It is also of interest to determine whether pathogens observed in BAL fluid were also present in sputum. Our findings show that organisms responsible for pneumonia were detected only in the BAL fluid in 29 of the 95 patients (31%) while all other samples, including sputum, had no diagnostic yield. The causative organisms were therefore not detected by less invasive procedures in 29 patients. Sputum was found to be useful in diagnosis in only 14% of the immunocompromised patients with pneumonia compared with 30% bronchial washings, 38% brushings, and 73% transbronchial biopsy specimens reported by Chopra. Transbronchial biopsy specimens were of diagnostic value in seven of 11 patients (64%) and relevant pathogens were cultured from BAL fluid in 65% of all patients in our study.

The value of BAL in the diagnosis of pneumonia in immunocompromised patients with different underlying diseases cited in the literature ranges from 33% to 83%. A diagnostic yield of 81% has been reported in

<table>
<thead>
<tr>
<th>Pathogens</th>
<th>Frequency (%)</th>
<th>Classification of pathogens</th>
<th>Frequency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Staphylococcus</em></td>
<td>23 (25.3%)</td>
<td>Gram positive</td>
<td>40.7%</td>
</tr>
<tr>
<td><em>Enterococcus</em></td>
<td>9 (9.9%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Streptococcus</em></td>
<td>3 (3.3%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>S aureus</em></td>
<td>2 (2.2%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Acinetobacter</em></td>
<td>1 (1.1%)</td>
<td>Gram negative</td>
<td>16.5%</td>
</tr>
<tr>
<td><em>Capnocytophaga</em></td>
<td>4 (4.4%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Chlamydia</em></td>
<td>2 (2.2%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Enterobacteriaceae</em></td>
<td>2 (2.2%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Haemophilus</em></td>
<td>2 (2.2%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Legionella</em></td>
<td>3 (3.3%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Pseudomonas</em></td>
<td>1 (1.1%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Mycobacterium</em></td>
<td>6 (6.6%)</td>
<td>Mycobacteria</td>
<td>6.6%</td>
</tr>
<tr>
<td><em>Candida</em></td>
<td>25 (27.5%)</td>
<td>Fungi</td>
<td>35.2%</td>
</tr>
<tr>
<td><em>Aspergillus</em></td>
<td>7 (7.7%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Cytomegalovirus</em></td>
<td>1 (1.1%)</td>
<td>Viruses</td>
<td>1.1%</td>
</tr>
</tbody>
</table>

www.thoraxjnl.com
Role of BAL in immunocompromised patients with pneumonia

Aspergillus pneumonia.²⁴ In an investigation performed by Stover et al, BAL had a diagnostic yield in 83% of all patients with invasive pulmonary aspergillosis confirmed by open lung biopsy, transbronchial biopsies, and necropsy. Von Eiff et al⁵ reported a sensitivity of 87% and a specificity of 100% for BAL. A single positive sputum culture for Aspergillus has to be viewed critically, while a positive BAL culture in immunocompromised patients should not be underestimated as contamination but should, in view of a mortality rate of approximately 14.8% reported for invasive pulmonary aspergillosis,²⁰ serve as an indication for the early onset of treatment with amphotericin B.²⁶ Aspergillus was cultured from BAL fluid in five of seven patients in our study. The two patients in whom BAL was not diagnostic were subsequently shown to have an aspergilloma which cannot be detected by BAL. One patient with a positive sputum culture for Aspergillus and a negative BAL finding underwent open lung biopsy with no evidence of invasive pulmonary aspergillosis, confirming the accuracy of the BAL findings obtained by our investigation. Marra et al⁶ found that Aspergillus was responsible for pneumonia in 20% of all patients with lymphoma. In our analysis of the 62 patients in our study in whom a pathogen was cultured from the BAL fluid showed that Aspergillus was responsible for pneumonia in 11% of patients.

Mycobacteria other than tuberculosis (MOTT)—for example, M. xenopi—are considered to be pathogenic in immunocompromised patients when cultured in a sterile medium such as BAL fluid or found in a biopsy specimen compatible with the clinical course. MOTT detected in a “non-sterile” medium such as sputum were considered to be pathogenic when more than 100 colonies could be seen in each of four different samples.²⁷ Although M. xenopi may occur in immunocompetent subjects as a contaminant, this is not the case in immunocompromised patients.

An important question remains if BAL findings are to be of therapeutic use in patients with BSAR, most of whom routinely receive this treatment. We detected pathogens responsible for pneumonia in the BAL fluid of 62 of the 95 patients (65%). Microbiological findings showed that the pathogens cultured from the BAL fluid were resistant to treatment in 38% of patients and to standard BSAR consisting of teicoplanin, ceftriaxon, tobramycin, and amphotericin B in 32% of all patients. There are few data in the literature to indicate whether BSAR consisting of teicoplanin, ceftriaxon, tobramycin, and amphotericin B is effective in the treatment of pathogens, or if the treatment regimen is changed after BAL. Marra et al⁶ reported that the standard BSAR was changed in 18% of patients as a result of BAL findings. Pathogens from the BAL fluid of patients with hospital acquired pneumonia were resistant to BSAR in 67% of cases⁶ and pathogens cultured from the BAL fluid of patients with immunosuppression were resistant in 43% of
cases. Empirical antimicrobial treatment was verified by bronchoscopy in 25 of 90 patients and was successfully changed in 34 patients. Our findings showed that causative pathogens detected exclusively in the BAL fluid in 29 of our 95 patients were resistant to the treatment given in 16 patients who would therefore have received inadequate treatment without BAL. Treatment with standard BSAR including teicoplanin, ceftriaxon, tobramycin, and amphotericin B would have been ineffective in 12 of 29 patients (41%) with pathogens detected in BAL fluid only.

Complications related to BAL consisted of minor self-limiting bleeding in 14.7% of patients; only one patient had more severe, non-haemodynamically relevant bleeding, although 77 of 95 patients were thrombocytopenic. No pneumothorax occurred. Studies on BAL related complications with a particular focus on immunocompromised patients have reported self-limiting bleeding, bronchial spasm, and coughing in 33% of patients. Von Eiff et al. noted that complications such as pneumothorax, respiratory symptoms requiring treatment in the intensive care unit, and self-limiting bleeding occurred in 5% of patients with haematological disorders, transplant recipients, or those with AIDS. Zavala reported bleeding following bronchoscopy in 26% of immunocompromised patients.

Thus, BAL may be considered to be a relatively safe procedure even for patients with a low platelet count when compared with the risk of untreated or unsuccessfully treated pneumonia in patients with neutropenia. In view of the cost of bronchoscopy (about 360 German marks or 180 Euro), this is a very small sum of money compared with the costs of a longer stay in hospital for severely ill patients. However, the question of cost effectiveness goes beyond the scope of this study. Our results suggest that BAL may be essential in the diagnosis of pneumonia in immunocompromised patients.

In conclusion, we have shown that the causative organisms were not detected by less invasive tools in 29 of 95 patients (31%) and that the pathogens found were resistant to BSAR in 12 of the 29 patients (41%). Even though 77 of 95 patients were thrombocytopenic, no major bleeding occurred. BAL is therefore a relatively safe procedure in the diagnosis of pneumonia in immunocompromised patients and in those treated with BSAR.

Role of bronchoalveolar lavage in immunocompromised patients with pneumonia treated with a broad spectrum antibiotic and antifungal regimen

I A Hohenadel, M Kiworr, R Genitsariotis, D Zeidler and J Lorenz

Thorax 2001 56: 115-120
doi: 10.1136/thorax.56.2.115

Updated information and services can be found at:
http://thorax.bmj.com/content/56/2/115

References
This article cites 26 articles, 2 of which you can access for free at:
http://thorax.bmj.com/content/56/2/115#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Drugs: infectious diseases (968)
- Pneumonia (infectious disease) (579)
- Pneumonia (respiratory medicine) (562)
- TB and other respiratory infections (1273)
- Radiology (diagnostics) (812)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/